Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Immunother Cancer ; 12(2)2024 02 28.
Article in English | MEDLINE | ID: mdl-38418395

ABSTRACT

Immune checkpoint inhibitor (ICI)-related hypophysitis (RH) is a common immune-related adverse event. The early detection of ICI-RH prevents life-threatening adrenal insufficiency. However, good predictors of secondary adrenal insufficiency in ICI-RH have not yet been reported. We hypothesized that fluctuations in plasma adrenocorticotropic hormone (ACTH) and cortisol levels occur similarly to those in thyroid-stimulating hormone and thyroid hormone (thyroxine and triiodothyronine) levels in ICI-related thyroiditis. Here, we sought to test this hypothesis. Patients who used ICI and had a history of measurement of plasma ACTH and serum cortisol concentrations were retrieved from electronic medical records, and those with a history of glucocorticoid use were excluded from the analysis. We evaluated fluctuations in plasma ACTH and serum cortisol concentrations and the development of ICI-RH. For patients with ICI-RH, data at three points (before ICI administration (pre), maximum ACTH concentration (peak), and onset of ICI-RH) were analyzed to evaluate hormone fluctuations. A total of 202 patients were retrieved from the medical record. Forty-three patients were diagnosed with ICI-RH. Twenty-six out of 43 patients had sufficient data to evaluate fluctuations in plasma ACTH and serum cortisol concentrations and no history of glucocorticoid use. ACTH concentrations changed from 37.4 (29.9­48.3) (pre) to 64.4 (46.5­106.2) (peak) pg/mL (1.72­fold increase, p=0.0026) in the patients with ICI-RH before the onset. There were no differences in cortisol concentrations between the pre and peak values in patients with ICI-RH. We also evaluated the fluctuations in plasma ACTH and serum cortisol levels in patients who did not receive ICI-RH (62 cases). However, elevation of plasma ACTH levels was not observed in patients without ICI-RH, suggesting that transient elevation of plasma ACTH levels is a unique phenomenon in patients with ICI-RH. In conclusion, plasma ACTH levels were transiently elevated in some patients with ICI-RH before the onset of secondary adrenal insufficiency. Monitoring the ACTH levels and their fluctuations may help predict the onset of ICI-RH.


Subject(s)
Adrenal Insufficiency , Hypophysitis , Humans , Adrenal Insufficiency/chemically induced , Adrenal Insufficiency/diagnosis , Adrenocorticotropic Hormone , Glucocorticoids/therapeutic use , Hydrocortisone , Hypophysitis/chemically induced , Immune Checkpoint Inhibitors/adverse effects , Immune Checkpoint Inhibitors/therapeutic use
2.
Intern Med ; 61(16): 2489-2495, 2022.
Article in English | MEDLINE | ID: mdl-35965075

ABSTRACT

An 82-year-old man was transferred to our hospital due to impaired consciousness. His albumin-corrected calcium level was 14.2 mg/dL, intact parathyroid hormone (PTH) and PTH-related protein levels were reduced, and his 1,25-dihydroxyvitamin D [1,25 (OH) 2VitD] level was elevated at 71.5 pg/mL. Computed tomography revealed masses on the bilateral ribs. The mass on the rib was biopsied and diagnosed as diffuse large B-cell lymphoma (DLBCL). Immunostaining of the biopsy sample with the anti-CYP27B1 antibody revealed the ectopic expression of 1α-hydroxylase in the lesion. We herein report a rare case of hypercalcemia induced by the overproduction of 1,25 (OH) 2VitD in DLBCL ectopically expressing 1α-hydroxylase.


Subject(s)
Hypercalcemia , Lymphoma, Large B-Cell, Diffuse , Aged, 80 and over , Calcifediol/adverse effects , Calcifediol/metabolism , Ectopic Gene Expression , Humans , Hypercalcemia/chemically induced , Lymphoma, Large B-Cell, Diffuse/complications , Male , Parathyroid Hormone/metabolism , Vitamin D/adverse effects
3.
Eur J Rheumatol ; 6(3): 158-160, 2019 07.
Article in English | MEDLINE | ID: mdl-30986168

ABSTRACT

In posterior reversible encephalopathy syndrome (PRES) triggered by scleroderma renal crisis (SRC), modulation and adherence in immunosuppressive therapy are key for avoiding recurrence, complications, and death. A patient with polymyositis (PM)/systemic sclerosis (SSc) overlap syndrome developed PRES triggered by SRC. To our knowledge, this is the first report of a case with PRES associated with PM/SSc overlap syndrome. This manifested as altered mental status and headaches. Vasogenic edema was seen by magnetic resonance imaging in the brainstem and cerebral white matter. Antihypertension therapy resulted in improvement in both neurological symptoms and blood pressure (BP). Reversible clinical course and radiological change were consistent with PRES diagnosis. Here, the importance of BP maintenance and removal of precipitating factors of PRES is shown.

SELECTION OF CITATIONS
SEARCH DETAIL
...